Skip to main content

Seegnal Inc. Announces Closing of First Tranche and Upsize and Extension of Private Placement

CALGARY, AB, Aug. 26, 2026 (GLOBE NEWSWIRE) — Seegnal Inc. (TSXV: SEGN) (“Seegnal” or the “Company”), a global leader in SaaS clinical decision support solutions, is pleased to announce, further to its news releases dated June 2, 2026 and July 21, 2026, that it has closed the first tranche (“Tranche 1”) of its previously announced non-brokered private placement of units in the capital of the Company (each, a “Unit”). The Company is also pleased to announce that it has upsized the private placement to up to CDN$1,850,000 and is expected to close the second tranche by September 30, 2026. The TSX Venture Exchange (the “TSXV”) has approved an extension and upsize for the Company to complete the non-brokered private placement for up to 6,607,143 Units for gross proceeds of up to CDN$1,850,000 at a price of $0.28 per Unit (the “Upsized...

Continue reading

Mesoblast Reports Substantial Revenue Growth to US$120M

RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment Financial Results and Operational Update for Full Year Ended June 30, 2026 NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026). Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026. The financial result is a product of continued growth in RYONCIL market adoption and focus on disciplined capital allocation while investing in our high-value opportunities. We plan to expand RYONCIL use to adults with severe steroid-refractory acute graft...

Continue reading

Humanoid Global Announces CEO Transition

– NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES – Vancouver, BC, Aug. 26, 2026 (GLOBE NEWSWIRE) — Humanoid Global Holdings Corp. (“Humanoid Global” or the “Company”) (CSE:ROBO, FWB:0XM1, OTCQB:RBOHF), a publicly traded investment issuer focused on building and accelerating a portfolio of pioneering companies in the humanoid robotics and embodied AI sector, announces a transition in its executive leadership. Shahab Samimi has resigned as Chief Executive Officer of the Company effective August 21, 2026. The Company wishes to thank Mr. Samimi for his contributions during his tenure and wishes him well in his future endeavours. The Company is also pleased to announce the appointment of Sunny Ray, a current member of the Company’s board of directors, as Chief Executive Officer of the Company, effective...

Continue reading

ReconAfrica Announces Grant of Stock Options and Restricted Share Units

CALGARY, Alberta, Aug. 26, 2026 (GLOBE NEWSWIRE) — Reconnaissance Energy Africa Ltd. (the “Company”, “ReconAfrica”) (TSXV: RECO) (OTCQX: RECAF) (Frankfurt: 0XD) (NSX: REC) announces that its Board of Directors has approved the grant of an aggregate of 7,715,900 stock options and 3,981,900 restricted share units to certain directors, officers, employees and consultants pursuant to the Company’s Option Plan and RSU/DSU Plan approved by shareholder at the AGM held on February 19, 2026. A total of 6,188,600 options and 3,484,200 restricted share units were granted to insiders. A total of 4,210,000 options expired since the previous granting of options on September 30, 2025. The Options are exercisable for common shares of the Company at $0.79 per share for a five-year term and vest in accordance with the Stock Option Plan. The RSUs...

Continue reading

Rainier Acquisition Corporation Announces Pricing of $75,000,000 Initial Public Offering

NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) — Rainier Acquisition Corporation (the “Company”) announced today that it priced its initial public offering of 7,500,000 units consisting of one Class A ordinary share and one-quarter of one redeemable warrant at a price of $10.00 per unit. The offering is expected to generate gross proceeds of $75,000,000 before underwriting discounts and offering expenses. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share. No fractional warrants will be issued upon separation of the units, and only whole warrants will trade. The units are expected to be listed on The Nasdaq Capital Market and trade under the ticker symbol “RNAQU” beginning August 27, 2026. Once the securities comprising the units begin separate trading,...

Continue reading

Globus Medical Announces Acquisition of Higgs Boson Health to Transform Healthcare Experience Through AI-Driven Digital Solutions

AUDUBON, Pa., Aug. 26, 2026 (GLOBE NEWSWIRE) — Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced the acquisition of Higgs Boson Health, a digital healthcare experience company based in Durham, NC and incubated out of Duke University. With a mission to transform healthcare experience through digital innovation, Higgs Boson will position Globus Medical to shape patient and provider experience throughout the full episode of care. “Higgs Boson employs highly experienced teams of software developers and AI scientists who will be joining our team to power our vision of a seamless digital healthcare environment to simplify a patient’s journey through our healthcare system while enhancing real-time information and surgical intelligence available to healthcare providers with the ultimate goal...

Continue reading

BranchOut Food Inc. Announces Proposed Public Offering

BEND, Ore., Aug. 26, 2026 (GLOBE NEWSWIRE) — BranchOut Food Inc. (Nasdaq: BOF) (“BranchOut” or the “Company”), a growth-stage consumer packaged foods company focused on developing, manufacturing, marketing and distributing clean-label, plant-based dried fruit and vegetable snacks, today announced that it has commenced an underwritten public offering (the “Offering”) of shares of its common stock to multiple investors. All of the shares in the Offering are to be sold by the Company. Lake Street Capital Markets, LLC is acting as the representative of the underwriters for the Offering. The Company expects to grant the representative a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the Offering solely to cover over-allotments. The Offering is subject to market and other conditions, and there...

Continue reading

Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients

– For patients with second-line (2L) metastatic pancreatic cancer, today’s FDA approval of a new treatment is an important milestone –  – For patients with first-line (1L) metastatic pancreatic cancer, Immuneering’s atebimetinib is being evaluated in a global randomized Phase 3 trial, MAPKeeper 301 – – 17.3-month median overall survival previously reported from Immuneering’s Phase 2a study of atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) in 1L pancreatic cancer – – In the same Phase 2a study, the only Grade 3+ treatment-related adverse events in ≥10% of patients were anemia (16%) and neutropenia (18%), both chemotherapy-related – NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients...

Continue reading

Methode Electronics Announces First Quarter Fiscal 2027 Results Conference Call

SOUTHFIELD, Mich., Aug. 26, 2026 (GLOBE NEWSWIRE) — Methode Electronics, Inc. (NYSE: MEI), a leading global supplier of custom-engineered solutions for power distribution, user interface, lighting, and sensor applications, today announced it will release its first quarter fiscal 2027 results for the period ended August 1, 2026, on Wednesday, September 2, 2026, after market close. The company will conduct a conference call and webcast the following day, Thursday, September 3, 2026, at 8:00 a.m. EST to review financial and operational highlights led by President and Chief Executive Officer, Jon DeGaynor, and Chief Financial Officer, Laura Kowalchik. To participate in the conference call, please dial (888) 506-0062 (U.S. domestic) or (973) 528-0011 (international) and provide participant code 335951, prior to the start of the event....

Continue reading

Xos Secures Follow-On Xos Hub™ Order from Xcel Energy to Provide Expedited and Flexible Fast Charging Opportunities for EVs in Colorado

Xos will supply an additional three Xos Hub™ mobile charging systems to support Xcel Energy fast charging capabilities at Colorado fleet sites and provide mobile charging for construction projectsXcel Energy orders three more Xos Hub™ units to charge fleet vehicles across different Colorado sites, to provide fast and flexible charging opportunities in a variety of use cases from semi-permanent to fully mobile Xos Hub units reach operability in days rather than the six to eighteen months typical of installation and set up to DC charging service Order follows Xos’s first deployment of two Hub units with Xcel Energy in 2024 amid growing Hub demand among utility and fleet customersLOS ANGELES, Aug. 26, 2026 (GLOBE NEWSWIRE) — Xos, Inc. (NASDAQ: XOS) (“Xos” or the “Company”), a leader in electric commercial vehicles...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.